
KRP-297 is a PPARα and PPARγ агонист potentially for the treatment of type 2 diabetes and dyslipidemia. KRP-297 restores reduced липид oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver.
KRP-297 is a PPARα and PPARγ agonist potentially for the treatment of type 2 diabetes and dyslipidemia. KRP-297 restores reduced lipid oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.